Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Zynex Q4 Earnings Report Analysis and Outlook

Elaine Mendonca by Elaine Mendonca
March 1, 2024
in Breaking News
0
Healthcare cloud based
0
SHARES
4
VIEWS
Share on FacebookShare on Twitter

Zynex, a publicly traded company on the NASDAQ under the ticker symbol ZYXI, recently shared its Q4 earnings report, providing valuable insights for investors to consider:

Earnings Performance:
Surprisingly, Zynex fell short of the estimated earnings by a significant margin of -76.0%, with an EPS of $0.04 compared to the expected $0.17.
Additionally, the company experienced a decrease in revenue of $1.52 million compared to the same period last year.

Past Earnings Performance:
In the previous quarter, Zynex surpassed EPS estimates by $0.01, resulting in a 17.0% increase in share price the following day.
To provide a comprehensive view of Zynex’s performance, here is a summary of their past earnings:
– Q3 2023: EPS Estimate $0.09, EPS Actual $0.10, Revenue Estimate $49.87 million, Revenue Actual $49.91 million
– Q2 2023: EPS Estimate $0.04, EPS Actual $0.09, Revenue Estimate $44.65 million, Revenue Actual $44.95 million
– Q1 2023: EPS Estimate $0.01, EPS Actual $0.04, Revenue Estimate $39.61 million, Revenue Actual $42.17 million
– Q4 2022: EPS Estimate $0.19, EPS Actual $0.20, Revenue Estimate $49.71 million, Revenue Actual $48.80 million

Upcoming Events:
Investors can mark their calendars for Zynex’s next earnings call, scheduled for Thursday, February 29, 2024, from 4:15 PM to 5:15 PM EST, where the company will discuss its performance for the fourth quarter and full year of 2024.

For more in-depth information and to stay updated on all earnings releases from Zynex, investors are encouraged to visit the company’s official website or financial platforms such as Nasdaq and TipRanks.

ZYXI Stock Analysis: Promising Performance on February 29, 2024

On February 29, 2024, ZYXI stock showed promising performances as it traded near the top of its 52-week range and above its 200-day simple moving average. This indicates that the stock has been on an upward trend and is considered to be in a bullish position. The price of ZYXI shares increased by $0.07 since the market last closed, representing a 0.52% rise. The stock closed at $13.56, showing a positive movement during regular trading hours. However, in after-hours trading, the stock dropped by $1.55. Despite the drop in after-hours trading, the overall performance of ZYXI stock on February 29, 2024, reflects a positive trend. Investors may want to keep an eye on the stock in the coming days to see if it continues its upward momentum or if there are any fluctuations in price.

ZYXI Stock Analysis: Strong Revenue Growth and Profitability Signals Positive Trajectory in Healthcare Sector

On February 29, 2024, ZYXI stock showed promising performances based on the financial data provided by CNN Money. The company’s total revenue for the past year was reported at $158.17 million, which represented a 21.39% increase compared to the previous year. In the third quarter alone, ZYXI generated $49.91 million in total revenue, marking an 11.04% increase from the previous quarter.

Despite the impressive revenue growth, ZYXI’s net income remained relatively flat compared to the previous year, standing at $17.05 million. However, the company managed to increase its net income by 7.16% in the third quarter, reaching $3.59 million. This improvement in net income is a positive sign for investors, indicating that ZYXI is effectively managing its expenses and increasing profitability.

Earnings per share (EPS) also saw positive growth trends for ZYXI. The company reported an EPS of $0.44 for the past year, reflecting a 9.83% increase compared to the previous year. In the third quarter, ZYXI’s EPS reached $0.10, showing a 10.06% increase from the previous quarter. This growth in EPS suggests that ZYXI is effectively translating its revenue growth into higher earnings for its shareholders.

Overall, ZYXI’s financial performance on February 29, 2024, indicates a strong and positive trajectory for the company. With consistent revenue growth, improving net income, and increasing earnings per share, ZYXI stock is likely to attract investors looking for a promising investment opportunity in the healthcare sector. Investors should keep an eye on ZYXI’s future financial reports to track the company’s continued growth and profitability.

Tags: ZYXI
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Biotechnology Markets and money

Precision BioSciences Announces Public Offering of Common Stock and Warrants

Software-solutions-technology

Autodesks Optimistic Projections for Fiscal Year 2025

Software-solutions-technology

Verra Mobilitys Q4 Earnings Report Revenue Surpasses Expectations Earnings Growth Expected

Recommended

Gold Stock

Gold Nears Historic Peak as Market Anticipation Builds

2 months ago
Dentist

Advancements in Oral Healthcare: The Business Impact of Highly Trained Surgeons

2 years ago
Archer Aviation Stock

Archer Aviation Strengthens Market Position Through Strategic Patent Acquisition

4 months ago
SNDR stock news

Yousif Capital Management LLC Reduces Stake in Steven Madden, Ltd.: Implications for the Company’s Future Performance

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Trending

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

by Rodolfo Hanigan
February 7, 2026
0

Investor attention is turning to the upcoming catalysts for Design Therapeutics, a biotechnology firm advancing its GeneTAC...

Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding
  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com